WO2012083274A3 - Methods for diagnosis, prognosis and methods of treatment - Google Patents

Methods for diagnosis, prognosis and methods of treatment Download PDF

Info

Publication number
WO2012083274A3
WO2012083274A3 PCT/US2011/065675 US2011065675W WO2012083274A3 WO 2012083274 A3 WO2012083274 A3 WO 2012083274A3 US 2011065675 W US2011065675 W US 2011065675W WO 2012083274 A3 WO2012083274 A3 WO 2012083274A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
activation
approach
cellular
cell population
Prior art date
Application number
PCT/US2011/065675
Other languages
French (fr)
Other versions
WO2012083274A2 (en
Inventor
Aileen Cohen
Alessandra Cesano
Wendy J. Fantl
Ying-Wen Huang
David Soper
David Rosen
Drew Hotson
Original Assignee
Nodality, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nodality, Inc. filed Critical Nodality, Inc.
Publication of WO2012083274A2 publication Critical patent/WO2012083274A2/en
Publication of WO2012083274A3 publication Critical patent/WO2012083274A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. The process is effective at characterizing MDS.
PCT/US2011/065675 2010-12-16 2011-12-16 Methods for diagnosis, prognosis and methods of treatment WO2012083274A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42391810P 2010-12-16 2010-12-16
US61/423,918 2010-12-16
US201161565935P 2011-12-01 2011-12-01
US61/565,935 2011-12-01

Publications (2)

Publication Number Publication Date
WO2012083274A2 WO2012083274A2 (en) 2012-06-21
WO2012083274A3 true WO2012083274A3 (en) 2014-04-10

Family

ID=46245410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/065675 WO2012083274A2 (en) 2010-12-16 2011-12-16 Methods for diagnosis, prognosis and methods of treatment

Country Status (1)

Country Link
WO (1) WO2012083274A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025847A2 (en) 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US9034257B2 (en) 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
US9738933B2 (en) 2012-12-05 2017-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
WO2018027144A1 (en) * 2016-08-04 2018-02-08 H. Lee Moffitt Cancer Center And Research Institute Inc. Companion diagnostic for combination lenalidomide and erythropoietin treatment
US11893499B2 (en) 2019-03-12 2024-02-06 International Business Machines Corporation Deep forest model development and training

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202451A1 (en) * 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
US20100009364A1 (en) * 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20100240542A1 (en) * 2009-03-23 2010-09-23 Nodality, Inc. Kits for multiparametric phospho analysis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050202451A1 (en) * 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
US20100009364A1 (en) * 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20100240542A1 (en) * 2009-03-23 2010-09-23 Nodality, Inc. Kits for multiparametric phospho analysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOLONICS, A. ET AL.: "Unregulated activation of STAT-5, ERK1/2 and c-Fos may contribute to the phenotypic transformation from myelodysplastic syndrome to acute leukaemia.", HAEMATOLOGIA., vol. 31, no. 2, 2001, pages 125 - 138 *

Also Published As

Publication number Publication date
WO2012083274A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
WO2015200893A3 (en) Methods of analyzing nucleic acids from individual cells or cell populations
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2011100708A3 (en) Assay card for sample acquisition, treatment and reaction
WO2006012507A3 (en) Methods and compositions for risk stratification
GB2568608A (en) Personalized genetic testing
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
WO2010062913A3 (en) Methods and systems for analysis of sequencing data
WO2012047618A3 (en) Mesothelioma biomarkers and uses thereof
WO2012061510A3 (en) Methods of predicting cancer cell response to therapeutic agents
WO2014071358A3 (en) Novel ntrk1 fusion molecules and uses thereof
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP4306955A3 (en) Integrated functional and molecular profiling of cells
WO2010056945A3 (en) Methods and systems for tissue processing and imaging
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2013164281A3 (en) Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
BRPI0811930B8 (en) methods and diagnostic or prognostic kit for lupus in an individual
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
WO2009032827A3 (en) Electroporative flow cytometry
EP3572529A3 (en) Gene methylation based colorectal cancer diagnosis
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
MX2015001961A (en) Assay methods and systems.

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15/10/2013)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11849327

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11849327

Country of ref document: EP

Kind code of ref document: A2